Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership

Concepts

• health services
• chloroquine monitoring service
• bradford district
• community service
• wakefield
• craven health and care partnership
• chloroquine monitoring service - bradford district
• community hydroxychloroquine
• routine monitoring of patients
• community provider

Location

Yorkshire and the Humber:

Description

A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline). however currently there is no service provision with BD&C HCP We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap.

Total Quantity or Scope

A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline).

Award Detail

CPV Codes

• 85100000 - Health services

Legal Justification

Routine monitoring of patients on Hydroxychloroquine (HCQ) is as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline), however currently there is no service provision with BD&C HCP. We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap. HCQ is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin (usually prescribed in rheumatology/dermatology). In general, it is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. However, some patients taking hydroxychloroquine, or a similar medication called chloroquine, can suffer permanent loss of vision due to retinopathy. As a result of this, once prescribed the guidelines recommend that a baseline is taken of a patient’s eye health, and dependent upon some other factors, once a patient has been on this drug for 5 years they should begin routine annual monitoring to ensure that the retina is maintaining health. The monitoring of these patients has not been undertaken in BD&C HCP, with Hospital Eye Services (HES) unable to take on the burden of these patients from either a capacity (HES services were and are already overflowing), or capability (lack of further clinic space). WY colleagues are now raising the risk index on this matter as they now believe we have patients who have been unmonitored on HCQ for 7 years or slightly greater (2 years beyond the guidelines for routine monitoring), although they are working with Meds Mgt teams to accurately identify the specific cohort and the number of patients involved. Justification under which formal quotation/tendering process is to be waived: (g) where specialist expertise/service/works/goods are required, and these are available from only one source (specialised service).

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **